Download PDF

CPNP 2020 industry supported symposia are scientific programs developed for educational purposes. All symposia at CPNP 2020 are designed for the psychiatric pharmacist and are included in participant registration fees. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation and provide 1.5 contact hours of ACPE credit.

Monday, April 27, 2:00-3:30 PM (CDT)

Cannabis Confusion: Sorting Out the Differences and Legality of CBD, Marijuana and Hemp Products

Rebroadcast dates

Tremendous interest has been generated in the medicinal potential from derivatives of the Cannabis species. The popularity of cannabidiol (CBD) oils for a huge variety of purposes has exploded, seemingly overnight. Intermixed with the excitement and hope is confusion about the many substances that can be derived from both the hemp and Cannabis sativa plants, how they differ from street drugs or home-grown, and how patients with serious illnesses can benefit from these agents in a safe and consistent manner. The legal/regulatory landscape for these substances are even more confusing.

This compelling symposium will provide a greater understanding of CBD and medical marijuana including a better understanding of the distinctions between Cannabis-derived substances such as CBD, including legal issues, purity, safety and efficacy of the FDA approved CBD agent, OTC CBD products and “street” products.

Learning Objectives

  • Apply available scientific information to counsel patients about the health benefits, concerns, and unknowns regarding medical marijuana and cannabidiol (CBD) containing agents, including both OTC and FDA approved agents
  • Explain the pharmacologic mechanisms of Cannabis-derived substances including CBD
  • Assess content of CBD/THC-containing agents available in medical dispensaries, including issues relating to purity, consistency, and dose
  • Differentiate among Cannabis substances including CBD, cannabinoids, oils, and street or home-grown plant-based substances
  • Discuss current laws relating to the purchase, distribution, and use of cannabis-derived agents and products


Jacquelyn L. Bainbridge, PharmD, FCCP
Professor, Clinical Pharmacy & Department of Neurology
University of Colorado Anschutz Medical Campus        Skaggs School of Pharmacy 
Aurora, CO
Laura Borgelt, PharmD, MBA, FCCP, BCPS
Professor and Associate Dean of Administration and Operations 
Clinical Pharmacy and Family Medicine
University of Colorado Anschutz Medical Campus 
Skaggs School of Pharmacy
Aurora, CO

Continuing Education


Pharmacy: Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-20-031-L03-P

Supported by

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Greenwich Bioscience.

Tuesday, April 28, 2:00-3:30 PM (CDT)

Advances in the Treatment of Schizophrenia: Integrating New and Emerging Options into Therapy to Meet Unmet Needs

Despite advances in treatment, schizophrenia continues to be one of the most challenging diseases for clinical pharmacists to manage. Antipsychotic medications are a mainstay of therapy, but they are also associated with high rates of nonadherence among patients, approaching 50% within the first year of treatment. Clinical psychiatric pharmacists must review patient-centered management strategies and assess appropriateness of therapy. Leveraging knowledge of efficacy, safety, and administration of pharmaceutical agents in clinical practice settings will allow pharmacists involved in the care of patients with schizophrenia to guide treatment decisions and improve overall patient outcomes. This activity will review the current treatment landscape of schizophrenia as well as evidence for novel therapies that have the potential to improve symptom management, optimize adherence, and reduce adverse effects.

Learning Objectives

  • Explain goals associated with acute phase and maintenance phase schizophrenia treatment and the need for updated treatment guidelines
  • Illustrate treatment challenges, risk of relapse and the subsequent impact on patient outcomes
  • Study new and emerging therapies, and their unique abilities to meet unmet needs
  • Identify how to safely and effectively incorporate new therapies into patient specific treatment plans


Lindsey N. Miller, PharmD, BCPP
Associate Professor
Department of Pharmacy Practice
Lipscomb University College of Pharmacy
Clinical Psychiatric Pharmacist
Vanderbilt Psychiatric Hospital
Nashville, Tennessee
Megan Maroney, PharmD, BCPP
Clinical Associate Professor
Ernest Mario School of Pharmacy
Rutgers, the State University of New Jersey
Clinical Psychiatric Pharmacist
Monmouth Medical Center
Long Branch, New Jersey

Supported by


Wednesday, April 29, 2:15-3:45 PM (CDT)

Achieving and Maintaining Improved Quality of Life in Patients with Tardive Dyskinesia

All patients prescribed an antipsychotic medication are at risk of developing tardive dyskinesia. Treatment for this disorder was once bleak, but with the developments and approval of VMAT2 inhibitors over the last few years, that has drastically changed. In this session, expert faculty will review the latest data on effective VMAT2 inhibitor treatment and demonstrate how to incorporate these medications into everyday clinical practice to improve the lives of patients with TD.

Learning Objectives

  • Outline the consequences of untreated TD on QoL in patients taking antipsychotic medications
  • Describe the clinical indications for and clinical benefits of administering the AIMS exam
  • Overcome barriers that interfere with patient adherence to VMAT2 inhibitors for the treatment of TD in order to improve patient QoL


Christoph U. Correll, MD
Professor of Psychiatry
Zucker School of Medicine at Hofstra/Northwell
Floral Park, New York
Stephen R. Saklad, PharmD, BCPP
Clinical Professor and Director of Psychiatric Pharmacy
The University of Texas at Austin
College of Pharmacy, Pharmacotherapy Division
Shavano Park, Texas

Continuing Education

In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit can be claimed online.

Offered by

North American Center for Continuing Medical Education (NACCME), an HMP Company

Supported by

Neurocrine Biosciences and Teva Pharmaceuticals